GlassScriptPhysician profile
Julia Janecki
NPI 1992496376
$637.75
in general payments reported to CMS, 2019-2025
18 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $131 · 2024: $128 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.99 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $48.44 | 2023-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $35.59 | 2023-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.42 | 2023-2025 | Lifevest |
| Neurelis, INC. | $27.97 | 2025 | Valtoco |
| Kiniksa Pharmaceuticals, LTD. | $27.37 | 2023 | Arcalyst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.36 | 2025 | Xifaxan |
| Organogenesis INC. | $24.03 | 2025 | Puraply Wound Matrix |
| Acera Surgical, INC. | $22.67 | 2025 | Restrata Wound Matrix |
| Neuros Medical, INC. | $19.78 | 2025 | Altius |
| Alexion Pharmaceuticals, INC. | $18.48 | 2024 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $18.48 | 2024 | |
| Kestra Medical Technology Services, INC. | $17.75 | 2023 | Assure Wcd |
| Scpharmaceuticals INC. | $16.53 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $16.10 | 2024 | Arcalyst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.94 | 2024 | |
| Genzyme Corporation | $14.58 | 2023 | |
| Lilly USA, LLC | $14.27 | 2024 | Zepbound, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Janecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.